<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362177</url>
  </required_header>
  <id_info>
    <org_study_id>20140346</org_study_id>
    <secondary_id>2017-002992-25</secondary_id>
    <nct_id>NCT03362177</nct_id>
  </id_info>
  <brief_title>Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer</brief_title>
  <official_title>RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with&#xD;
      Gastrointestinal, Pancreatic, or Colorectal Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RECITE: A phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the&#xD;
      Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based&#xD;
      Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.</measure>
    <time_frame>48 days</time_frame>
    <description>No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 10 9/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depth of Platelet Count</measure>
    <time_frame>48 days</time_frame>
    <description>the depth of the platelet count nadir from the start of the first on-study chemotherapy cycle through the end of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First platelet response</measure>
    <time_frame>7 Days</time_frame>
    <description>The time to first platelet response, defined by platelet count ≥ 100 x 109/L in the absence of platelet transfusions during the preceding 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>48 days</time_frame>
    <description>the duration-adjusted event rate of&#xD;
≥ grade 2 bleeding events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-year</time_frame>
    <description>1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of Platelet Transfusion</measure>
    <time_frame>48 days</time_frame>
    <description>platelet transfusion(s) during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>7 days</time_frame>
    <description>achieving a platelet count equal to or greater than 100 x 10 9/L at any time after study day 1 to week 4 (ie, 7 days after the planned third dose of investigational product) and in the absence of platelet transfusions during the preceding 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs/SAEs overall safety of romiplostim</measure>
    <time_frame>36 months</time_frame>
    <description>Through end of study, up to 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Chemotherapy-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Romiplostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.</description>
    <arm_group_label>Romiplostim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures or subject's legally acceptable representative has provided&#xD;
             informed consent prior to any study-specific activities/procedures being initiated&#xD;
             when the subject has any kind of condition that, in the opinion of the investigator,&#xD;
             may compromise the ability of the subject to give written informed consent.&#xD;
&#xD;
          -  Males or females 18 years of age at signing of the informed consent.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of gastrointestinal, pancreatic,&#xD;
             or colorectal adenocarcinoma, defined as cancers of the esophagus, stomach, pancreas,&#xD;
             colon, or rectum. Tumor stage will not affect eligibility.&#xD;
&#xD;
          -  Subjects must be receiving 1 of the following regimens:&#xD;
&#xD;
          -  An oxaliplatin-based chemotherapy regimen, containing 5 FU or capecitabine plus&#xD;
             oxaliplatin (irinotecan may be added for FOLFIRINOX or FOLFOXIRI) on a 14- or 21 day&#xD;
             schedule, respectively. Note: Use of these regimens are permitted with (1) anti&#xD;
             angiogenic agents (such as bevacizumab) or (2) targeted therapy (such as anti&#xD;
             epidermal growth factor receptor agents).&#xD;
&#xD;
          -  Subjects must have a platelet count &lt; 75 x 10(9)/L on study day 1.&#xD;
&#xD;
          -  Subjects must be at least 14 days removed from the start of the chemotherapy cycle&#xD;
             immediately prior to study day 1 if they received FOLFOX, FOLFIRINOX or FOLFOXIRI, and&#xD;
             21 days removed if they received CAPEOX.&#xD;
&#xD;
          -  Subjects must have at least 3 remaining planned cycles of chemotherapy at study&#xD;
             enrollment.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Previous or Current Medical Conditions&#xD;
&#xD;
          -  Acute lymphoblastic leukemia.&#xD;
&#xD;
          -  Acute myeloid leukemia.&#xD;
&#xD;
          -  Any myeloid malignancy.&#xD;
&#xD;
          -  Myelodysplastic syndrome. Baseline bone marrow biopsy is not required to rule out MDS.&#xD;
             However, if a bone marrow biopsy and cytogenetics were performed as part of diagnostic&#xD;
             or staging work-up, these results will be collected to confirm.&#xD;
&#xD;
          -  Myeloproliferative disease.&#xD;
&#xD;
          -  Multiple myeloma.&#xD;
&#xD;
          -  Within 4 months prior to enrollment, any history of active congestive heart failure&#xD;
             (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia,&#xD;
             uncontrolled arrhythmias, clinically significant electrocardiogram (ECG)&#xD;
             abnormalities, screening ECG with corrected QT (QTc) interval of 470 msec, pericardial&#xD;
             disease, or myocardial infarction.&#xD;
&#xD;
          -  Major surgery ≤ 28 days or minor surgery ≤ 3 days prior to enrollment.&#xD;
&#xD;
          -  New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior&#xD;
             to screening. To be eligible, subjects must have received at least 14 days of&#xD;
             anticoagulation for a new thrombotic event and considered to be both stable and&#xD;
             suitable for continued therapeutic anticoagulation during trial participation.&#xD;
&#xD;
          -  History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6&#xD;
             months of screening.&#xD;
&#xD;
          -  Evidence of active infection within 2 weeks prior to first dose of study treatment.&#xD;
&#xD;
          -  Known human immunodeficiency virus infection. Subjects without a documented diagnosis&#xD;
             in their medical history will require a central laboratory assessment at screening.&#xD;
&#xD;
          -  Known active chronic hepatitis B or C infection. Subjects without a documented&#xD;
             diagnosis in their medical history will require a central laboratory assessment at&#xD;
             screening. Hepatitis B and C infection is based on the following results:&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or&#xD;
             recent acute hepatitis B).&#xD;
&#xD;
          -  Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by&#xD;
             polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA&#xD;
             suggests occult hepatitis B.&#xD;
&#xD;
          -  Positive Hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is&#xD;
             necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.&#xD;
&#xD;
          -  Secondary malignancy within the past 5 years except:&#xD;
&#xD;
          -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of&#xD;
             disease.&#xD;
&#xD;
          -  Adequately treated cervical carcinoma in situ without evidence of disease.&#xD;
&#xD;
          -  Adequately treated breast ductal carcinoma in situ without evidence of disease.&#xD;
&#xD;
          -  Prostatic intraepithelial neoplasia without evidence of prostate cancer.&#xD;
&#xD;
          -  Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.&#xD;
&#xD;
          -  Malignancy treated with curative intent and with no known active disease present for 3&#xD;
             years before enrollment and felt to be at low risk for recurrence by the treating&#xD;
             physician&#xD;
&#xD;
          -  Thrombocytopenia due to another etiology other than CIT (eg, chronic liver disease,&#xD;
             prior history of immune thrombocytopenia purpura).&#xD;
&#xD;
        Prior/Concomitant Therapy&#xD;
&#xD;
        • Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and&#xD;
        development factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or&#xD;
        any investigational platelet producing agent.&#xD;
&#xD;
        Prior/Concurrent Clinical Study Experience • Currently receiving treatment in another&#xD;
        investigational device or drug study, or less than 28 days since ending treatment on&#xD;
        another investigational device or drug study(ies). Other investigational procedures while&#xD;
        participating in this study are excluded.&#xD;
&#xD;
        Diagnostic Assessments&#xD;
&#xD;
          -  Anemia (hemoglobin 8 g/dL) on the day of initiation of investigational product as&#xD;
             assessed by local labs. Use of red cell transfusions and erythropoietic stimulating&#xD;
             agents is permitted throughout the study as per institutional guidelines.&#xD;
&#xD;
          -  Neutropenia (absolute neutrophil count 1 x 109/L) on the day of initiation of&#xD;
             investigational product as assessed by local labs. Use of granulocyte-colony&#xD;
             stimulating factor is permitted throughout the study as per institutional guidelines.&#xD;
&#xD;
          -  Abnormal renal function with creatinine clearance 30 mL/min using the Cockcroft-Gault&#xD;
             estimated creatinine clearance as assessed by central laboratory during screening.&#xD;
&#xD;
          -  Abnormal liver function (total bilirubin 3X ULN; alanine aminotransferase [ALT] or&#xD;
             aspartate aminotransferase [AST] 3X ULN for subjects without liver metastases or 5X&#xD;
             ULN for subjects with liver metastases) as assessed by central laboratory during&#xD;
             screening.&#xD;
&#xD;
        Other Exclusions&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed&#xD;
             during treatment and for an additional 6 months after treatment (and chemotherapy)&#xD;
             discontinuation (females of childbearing potential should only be included after a&#xD;
             confirmed menstrual period and a negative highly sensitive urine or serum pregnancy&#xD;
             test.)&#xD;
&#xD;
          -  Females of childbearing potential unwilling to use a highly effective method of&#xD;
             contraception during treatment and for an additional 6 months after treatment (and&#xD;
             chemotherapy) discontinuation.&#xD;
&#xD;
          -  Males unwilling to use contraception* (male condom or sexual abstinence) or their&#xD;
             female partner(s) of childbearing potential who are unwilling to use a highly&#xD;
             effective method of contraception during treatment (and chemotherapy) and for an&#xD;
             additional 6 months after treatment (and chemotherapy) discontinuation.&#xD;
&#xD;
             *If the male's sole partner is of non-childbearing potential, he is not required to&#xD;
             use additional forms of contraception during the study.&#xD;
&#xD;
          -  Subject has known sensitivity to any of the products to be administered during dosing.&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures (eg, COAs) to the best&#xD;
             of the subject and investigator's knowledge.&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition or disease&#xD;
             (with the exception of those outlined above) that, in the opinion of the investigator&#xD;
             or Amgen physician, if consulted, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures or completion.&#xD;
&#xD;
          -  Male subjects with a pregnant partner who are unwilling to practice abstinence or use&#xD;
             a condom during treatment (and chemotherapy) and for an additional period of 6 months&#xD;
             after treatment (and chemotherapy) discontinuation.&#xD;
&#xD;
          -  Male subjects unwilling to abstain from donating sperm during treatment (and&#xD;
             chemotherapy) and for an additional 6 months after treatment (and chemotherapy)&#xD;
             discontinuation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California at Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado West Healthcare System dba Grand Valley Oncology</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Centers PA</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of West Broward, PA</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christus Saint Frances Cabrini Hospital</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Highland Cancer Treatment Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Favaloro</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1093AAS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico Cordoba</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clínicas Clínica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>Río Negro</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Steyr</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia do Parana</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80530-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vencer e Oncoclinica</name>
      <address>
        <city>Teresina</city>
        <state>Piauí</state>
        <zip>64049-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa da Serra Gaucha - Cepesg</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande Do Sul</state>
        <zip>95020-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loema Instituto de Pesquisa Clinica &amp; Consultores Ltda</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13010-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa de Saude Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>08270-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Nadezhda Clinical EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Oncology EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cape Breton Cancer Centre, Nova Scotia Health Authority</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1P 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre at Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Colombiana de Cancerologia Clinica Vida</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncomedica Imat</name>
      <address>
        <city>Monteria</city>
        <state>Córdoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Brest</name>
      <address>
        <city>Brest cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Aretaieio Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evgenidio Hospital I Agia Trias</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Oncology Hospital of Kifissia Agioi Anargyroi</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agios Loukas Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55236</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Egyetemi Oktato Korhaz</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Szent Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncotech</name>
      <address>
        <city>La Paz</city>
        <state>Baja California Sur</state>
        <zip>23040</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion e Investigacion Cardiovascular del Potosi Sc</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potosí</state>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional Siglo XXI</name>
      <address>
        <city>Mexico</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization SC</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Goyeneche</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncosalud</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej</name>
      <address>
        <city>Biala Podlaska</city>
        <zip>21-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Powiatowe Centrum Zdrowia w Brzezinach Sp Z o o</name>
      <address>
        <city>Brzeziny</city>
        <zip>95-060</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Pozn</name>
      <address>
        <city>Poznan</city>
        <zip>60-780</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitario do Porto EPE - Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinica de Diagnostic Rapid</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute for Digestive Disorders and Liver Transplantation</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic al Cailor Ferate Cluj Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Medisprof SRL</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400124</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Sf Nectarie SRL</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI of Arkhangelsk region Arkhangelsk clinical oncology dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Autonomic SHI Republican clinical oncology dispensary of MoH of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medsi Group</name>
      <address>
        <city>Moscow Region</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical hospital 2, Group of companies medsi</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Tonus</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State budget institution of public health Pyatigorsk oncology dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Dispensary na L D Roman</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI Scientific and Research Oncology Institute named after N N Petrov</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health Oncology Dispensary 2 of Public Health Krasnodar Region</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>State Institution of Public Health Tambov Regional Oncology Dispensary</name>
      <address>
        <city>Tambov</city>
        <zip>390013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova Lleida</name>
      <address>
        <city>Lleida</city>
        <state>Cataluña</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Cataluña</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria Nai</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baskent Universitesi Adana Doktor Turgut Noyan Uygulama ve Arastirma Merkezi</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doktor Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Sehir Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Onkoloji Enstitusu</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Cemil Tascioglu Sehir Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34384</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hastanesi</name>
      <address>
        <city>Izmir</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Arastirma ve Uygulama Hastanesi</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VM Medical Park Samsun Hastanesi</name>
      <address>
        <city>Samsun</city>
        <zip>55200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Institution Chernivtsi Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prykarpatskyy Clinical Oncology Centre</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Clinical Oncological Dispensary</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy Induced Thrombocytopenia</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

